Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema

Summary

Up to one out of five patients with breast cancer will develop lymphedema in the upper extremity after cancer treatment. Patients with breast cancer-related lymphedema (BCRL) suffer from pain, heaviness, tightness, and a decreased range of motion. Photobiomodulation therapy (PBMT) is a non-invasive therapy based on the application of visible and/or near-infrared light produced by a laser diode or a light-emitting diode. The scientifically proven biologic effects of PBM are improved wound healing, and a reduction in pain, inflammation, and oedema. Therefore, the aim of this study is to evaluate the effectiveness of PBMT on the management of BCRL.

Eligibility

Inclusion Criteria:

* Diagnosed with breast cancer
* Underwent ipsilateral lumpectomy or mastectomy + sentinel lymph node biopsy +/- lymph node dissection
* Underwent radiotherapy with or without chemotherapy
* Diagnosed with BCRL (i.e. International Society of Lymphology (ISL) lymphedema stage I or higher)
* Age ≥ 18 years
* Able to comply to the study protocol
* Able to sign written informed consent

Exclusion Criteria:

* Metastatic disease
* Pregnancy
* History of surgery or trauma to the arm
* History of arm infection in the past 3 months
* Use of medications that affect body fluid (e.g., diuretics) in the last 3 months
* Severe psychological disorder or dementia
* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator

Conditions4

Browse More Trials